stemedb/latent/vision.md

Latent

The safety signal is already there. You just aren't listening.

The Problem

Clinical trials are sterile. The real world is messy.

In Phase III, 3,000 carefully selected patients take a drug. They are monitored, compliant, and healthy. In the real world, 3,000,000 people take it. They mix it with alcohol, herbal supplements, and bad diets. They forget doses. They are biologically messy.

Signals emerge in the real world years before they hit the FDA label.

• A Reddit cluster discussing "strange vivid dreams" 18 months before the label update.
• A contradiction between the EU label (warning added) and the US label (silent).
• A drop in refill rates in a specific demographic that implies a hidden side effect.

Pharma safety teams (Pharmacovigilance) are drowning in PDFs and manual reviews. They operate on "Consensus." They miss the Latent signal until it becomes a class-action lawsuit.

The Solution

Latent is an active surveillance engine for epistemic risk in pharmacology.

It ingests the noisy, conflicting, messy stream of global health data:

• Tier 0: FDA/EMA/PMDA Regulatory Actions
• Tier 1: ClinicalTrials.gov results, Phase IV commitments
• Tier 2: PubMed/Lancet publications, Case Reports
• Tier 4: De-identified EHR aggregates
• Tier 5: Patient forums (Reddit, PatientsLikeMe), Social sentiment

It doesn't just "search" for side effects. It graphs the Divergence.

How It Feels

You are a Safety Medical Director tracking Semaglutide.

You don't see a static report. You see a Conflict Heatmap.

┌────────────────────────────────────────────────────────┐
│ MOLECULE: Semaglutide (Ozempic/Wegovy)                 │
│ STATUS:   DIVERGENT ⚠️ (Score: 0.82)                   │
│                                                        │
│ [ Official Safety Profile (Tier 0) ]                   │
│ ✅ GI Issues: Nausea, Vomiting (Common)                │
│ ✅ Thyroid C-Cell Tumors: Warning (Rare)               │
│                                                        │
│ [ Latent Signal Detected ]                             │
│ 🔥 Gastroparesis (Stomach Paralysis)                   │
│    ├─ Signal Strength: High                            │
│    ├─ First Detected:  Q2 2023 (Reddit Cluster)        │
│    ├─ Corroborated:    Q4 2023 (3 Case Studies)        │
│    └─ Conflict:        Directly contradicts "Transient"│
│                        label claim.                    │
│                                                        │
│ [ Action ]                                             │
│ The FDA label is lagging the Latent Signal by ~8 mo.   │
│ Recommend: Phase IV observational study focus.         │
└────────────────────────────────────────────────────────┘

Core Principles

1. Disagreement is Data

Most safety software treats "anecdotal" reports as noise to be filtered. Latent treats them as Tier 5 Signals. A single tweet is noise. A cluster of 500 tweets describing the same specific symptom is a Signal that outweighs a 2-year-old Clinical Trial.

2. Time-Travel Liability

"What did we know, and when did we know it?" Latent allows Time-Travel Queries. You can scroll back to June 14, 2023, and see exactly what the epistemic state was.

• Did the public know? Yes.
• Did the literature know? No. This protects against negligence ("We acted as soon as the Tier 2 signal emerged") or exposes it.

3. The "Skeptic" Lens

Latent doesn't optimize for "Truth." It optimizes for Risk. It assumes the official label is always decaying. It actively hunts for the "Black Swan" event that breaks the current safety model.

Use Cases

For Pharma (Pharmacovigilance)

• Early Warning: Detect adverse events in the wild before the FDA mandates a warning letter.
• Label Defense: Proactively update labels to limit liability.
• Competitive Intel: "Our competitor's drug is showing a latent cardiac signal in Europe. Ours isn't."

For Hedge Funds / BioTech Investors

• The "Short" Signal: Latent detects a safety signal for a blockbuster drug 6 months before the market. The fund shorts the stock before the recall.
• Trial Prediction: Analysis of early patient chatter predicts trial failure/success before publication.

Technical Foundation

Latent is the "Pharma-Tuned" implementation of Episteme:

• Source Class: Heavily utilized. Regulatory (0) vs Clinical (1) vs Social (5) is the core logic.
• Decay: Aggressive decay on Social data (noise fades fast), Zero decay on Regulatory (law is law).
• Materialized Views: Pre-computed risk scores for every tracked molecule.

The Name

Latent. Because the side effects haven't happened yet. They are waiting.

---

Safety is not the absence of evidence. It is the evidence of absence.